Trial Profile
Study of the immune system modulations of melanoma patients treated with anti -PD1 monoclonal antibodies [Etude des modulations du système immunitaire des patients atteints de mélanome et traités par anticorps monoclonaux anti-PD1]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 07 Jul 2018 Status changed from recruiting to completed.
- 21 Aug 2015 New trial record